Should I Buy COO? COO 2026 Analysis

Should You Buy Cooper Companies Inc (COO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

82.100

1 Day change

2.50%

52 Week Range

95.430

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now for a tactical rebound setup: price is sitting just above the pivot (81.21) after a strong +3.23% up-day, with upside room to first resistance 83.12 then 84.30.
Options sentiment is clearly bullish (calls dominant) despite elevated IV, suggesting traders are positioning for upside rather than protection.
Wall Street is mostly constructive (many Buy/Overweight ratings with targets clustered ~91–99), implying meaningful upside vs. 81.87, though one notable bear (Goldman Sell) remains.
No supportive news flow this week, so the near-term move is more technical/sentiment-driven until the next event (earnings 2026-03-05).
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/momentum: MACD histogram is negative (-0.393) and expanding lower → underlying downtrend momentum still present even after today’s bounce.
RSI (6): 29.39 → near oversold territory, consistent with a mean-reversion bounce risk-on entry rather than a confirmed trend reversal.
Moving averages: converging MAs → selling pressure may be stabilizing, but not yet a clear uptrend.
Key levels: Pivot 81.21 (price 81.87 slightly above = constructive). Supports: 79.30 then 78.12. Resistances: 83.12 then 84.30.
Pattern-based forward odds: modest positive bias (model suggests small gains over 1D/1W/1M), supporting a near-term bounce thesis rather than a breakout call.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Put/Call positioning: Open interest P/C 0.39 and volume P/C 0.10 → calls dominate, signaling bullish positioning.
Implied volatility: 30D IV 46.65 vs historical vol 27.79 → options are pricing elevated moves (expensive premiums), consistent with heightened expectations.
IV percentile: 96.8 → extremely high versus its own history, often seen around event-risk windows or after sharp moves.
Activity: total volume 127; call volume 115 vs put volume 12 → flow is strongly skewed bullish.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical mean-reversion potential: near-oversold RSI plus a strong up-day off the pivot supports continued rebound attempts.
- Analyst target skew upward: multiple firms reiterate Buy/Overweight with targets mostly in the low-to-high 90s.
- Earnings ahead (2026-03-05 After Hours): upcoming event can re-rate the stock if guidance/margins improve.
- Operational narrative (from analyst notes): stabilizing growth trends and cost actions have been highlighted as improving the setup.

Neutral/Negative Catalysts

- Momentum still bearish: MACD continues to weaken, so the bounce may fail near 83–84 resistance without follow-through.
- Profitability deterioration: latest quarter showed sizable YoY declines in net income, EPS, and gross margin.
- Competitive risk: Needham flagged potential Paragard pressure from Sebela’s Miudella launch (mid-2026), with possible FY27 EPS headwind.
- No fresh news this week: fewer near-term narrative catalysts until earnings, increasing reliance on technicals/flow.

Financial Performance

Latest quarter: 2025/Q4
Revenue: $1.065B, +4.59% YoY (top-line growth remained positive).
Net income: $84.6M, -28.0% YoY (profit compression).
EPS: $0.43, -27.12% YoY (earnings down sharply despite revenue growth).
Gross margin: 56.43%, down ~8.42% YoY (margin pressure is the key fundamental negative in the quarter).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: price targets were broadly raised after FY2025/Q4, then Needham slightly trimmed (99 from 100) while maintaining Buy.
Bullish camp: Barclays (Overweight, PT 98), Baird (Outperform, PT 98), Piper Sandler (Overweight, PT 94), Stifel (Buy, PT 95), Needham (Buy, PT 99) → thesis centers on stabilizing trends and operating leverage/cost actions.
Neutral camp: Citi (Neutral, PT 88), JPMorgan (Neutral, PT 78) → acknowledges improvement but sees higher bar in outlook/earnings delivery.
Bear case: Goldman Sachs (Sell, PT 73) → expects valuation to re-align more tightly to organic growth; sees prior stock performance outpacing fundamentals.
Wall Street pros vs cons: Pros = stabilization + potential margin/cost upside + targets imply upside; Cons = margin/EPS deterioration in latest quarter + looming Paragard competition + one prominent Sell view.

12 Analyst Rating

Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 90.33 USD with a low forecast of 73 USD and a high forecast of 100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

4 Hold

1 Sell

Moderate Buy

Current: 80.100

Low

Averages

90.33

High

100

Current: 80.100

Low

Averages

90.33

High

100

Needham

Buy

downgrade

$100 -> $99

AI Analysis

2026-02-03

Reason

Needham

Price Target

$100 -> $99

AI Analysis

2026-02-03

downgrade

Buy

Reason

Needham lowered the firm's price target on Cooper Companies to $99 from $100 and keeps a Buy rating on the shares. Ahead of Sebela's mid-2026 Miudella launch, the firm spoke to a couple of OB/GYNs to learn how it might impact their utilization of COO's Paragard, and the doctors on average expect Miudella to take up to 5% of their total Paragard volume, which could increase if Miudella's ongoing study results in a longer-term label, the analyst tells investors in a research note. Needham estimates Cooper could face up to 90 bps of EPS pressure in FY27 from Paragard competition.

Barclays

NULL -> Overweight

maintain

$97 -> $98

2026-01-26

Reason

Barclays

Price Target

$97 -> $98

2026-01-26

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Cooper Companies to $98 from $97 and keeps an Overweight rating on the shares. The firm made minor changes to the company's model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for COO

Unlock Now

COO Should I Buy

COO Should I Buy

Should You Buy Cooper Companies Inc (COO) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch